{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:08:16Z","timestamp":1791403696910,"version":"4.3.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T00:00:00Z","timestamp":1403136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s40263-014-0168-0","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T12:42:47Z","timestamp":1403181767000},"page":"641-648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis"],"prefix":"10.1007","volume":"28","author":[{"given":"Carmen","family":"Tur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,19]]},"reference":[{"issue":"1","key":"168_CR1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","volume":"348","author":"DH Miller","year":"2003","unstructured":"Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15\u201323.","journal-title":"N Engl J Med"},{"issue":"9","key":"168_CR2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910.","journal-title":"N Engl J Med"},{"issue":"9","key":"168_CR3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911\u201323.","journal-title":"N Engl J Med"},{"issue":"6","key":"168_CR4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.33588\/rn.5206.2010766","volume":"52","author":"A Horga","year":"2011","unstructured":"Horga A, Castillo J, Rio J, et al. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev Neurol. 2011;52(6):321\u201330.","journal-title":"Rev Neurol"},{"issue":"4","key":"168_CR5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375\u201381.","journal-title":"N Engl J Med"},{"issue":"3676","key":"168_CR6","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1126\/science.148.3676.1477","volume":"148","author":"G Zurhein","year":"1965","unstructured":"Zurhein G, Chou SM. Particles resembling papova viruses in human cerebral demyelinating disease. Science. 1965;148(3676):1477\u20139.","journal-title":"Science"},{"issue":"2","key":"168_CR7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","volume":"18","author":"PS Sorensen","year":"2012","unstructured":"Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2):143\u201352.","journal-title":"Mult Scler"},{"key":"168_CR8","unstructured":"Biogen Idec\u00ae Official Site. http:\/\/www.biogenidec-international.com\/tysabri_fact_sheet.aspx?ID=4698 . Accessed Oct 2013."},{"key":"168_CR9","unstructured":"PubMed\u00ae Official Site. http:\/\/www.ncbi.nlm.nih.gov\/pubmed . Accessed Oct 2013."},{"issue":"15","key":"168_CR10","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430\u20138.","journal-title":"Neurology"},{"issue":"5","key":"168_CR11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/infdis\/jiq097","volume":"203","author":"MK White","year":"2011","unstructured":"White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy\u2014revisited. J Infect Dis. 2011;203(5):578\u201386.","journal-title":"J Infect Dis"},{"issue":"5","key":"168_CR12","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","volume":"72","author":"TA Yousry","year":"2012","unstructured":"Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012;72(5):779\u201387.","journal-title":"Ann Neurol"},{"issue":"1","key":"168_CR13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/1352458508096870","volume":"15","author":"E Iacobaeus","year":"2009","unstructured":"Iacobaeus E, Ryschkewitsch C, Gravell M, et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler. 2009;15(1):28\u201335.","journal-title":"Mult Scler"},{"issue":"Suppl 1","key":"168_CR14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/13550280390195298","volume":"9","author":"P Cinque","year":"2003","unstructured":"Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol. 2003;9(Suppl 1):88\u201392.","journal-title":"J Neurovirol"},{"issue":"3","key":"168_CR15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1001\/jamaneurol.2013.1960","volume":"70","author":"AL Boster","year":"2013","unstructured":"Boster AL, Nicholas JA, Topalli I, et al. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol. 2013;70(3):398\u2013402.","journal-title":"JAMA Neurol"},{"issue":"11","key":"168_CR16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352.","journal-title":"Neurology"},{"issue":"20","key":"168_CR17","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870\u201380.","journal-title":"N Engl J Med"},{"issue":"4","key":"168_CR18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/infdis\/147.4.676","volume":"147","author":"PM Chesters","year":"1983","unstructured":"Chesters PM, Heritage J, McCance DJ. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis. 1983;147(4):676\u201384.","journal-title":"J Infect Dis"},{"issue":"6","key":"168_CR19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","volume":"199","author":"A Egli","year":"2009","unstructured":"Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis. 2009;199(6):837\u201346.","journal-title":"J Infect Dis"},{"issue":"7","key":"168_CR20","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/jmv.23585","volume":"85","author":"N Zanotta","year":"2013","unstructured":"Zanotta N, Delbue S, Rossi T, et al. Molecular epidemiology of JCV genotypes in patients and healthy subjects from Northern Italy. J Med Virol. 2013;85(7):1286\u201392.","journal-title":"J Med Virol"},{"issue":"9","key":"168_CR21","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1177\/1352458512466165","volume":"19","author":"J Havla","year":"2013","unstructured":"Havla J, Berthele A, Kumpfel T, et al. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab \u201cinfusion group\u201d. Mult Scler. 2013;19(9):1213\u20135.","journal-title":"Mult Scler"},{"issue":"2","key":"168_CR22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir256","volume":"204","author":"CE Reid","year":"2011","unstructured":"Reid CE, Li H, Sur G, et al. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis. 2011;204(2):237\u201344.","journal-title":"J Infect Dis"},{"issue":"1","key":"168_CR23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1743-422X-10-298","volume":"10","author":"A Bellizzi","year":"2013","unstructured":"Bellizzi A, Anzivino E, Rodio DM, et al. Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study. Virol J. 2013;10(1):298.","journal-title":"Virol J"},{"issue":"1","key":"168_CR24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/infdis\/jir198","volume":"204","author":"L Gorelik","year":"2011","unstructured":"Gorelik L, Reid C, Testa M, et al. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis. 2011;204(1):103\u201314.","journal-title":"J Infect Dis"},{"issue":"11","key":"168_CR25","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/jnnp-2012-304332","volume":"84","author":"C Warnke","year":"2013","unstructured":"Warnke C, Ramanujam R, Plavina T, et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1199\u2013205.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"168_CR26","doi-asserted-by":"crossref","first-page":"e1003014","DOI":"10.1371\/journal.ppat.1003014","volume":"8","author":"MR Perkins","year":"2012","unstructured":"Perkins MR, Ryschkewitsch C, Liebner JC, et al. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS pathog. 2012;8(11):e1003014.","journal-title":"PLoS pathog"},{"issue":"16","key":"168_CR27","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0b013e3182a84101","volume":"81","author":"C Warnke","year":"2013","unstructured":"Warnke C, Mausberg AK, Stettner M, et al. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology. 2013;81(16):1400\u20138.","journal-title":"Neurology"},{"issue":"10","key":"168_CR28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","volume":"81","author":"N Schwab","year":"2013","unstructured":"Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81(10):865\u201371.","journal-title":"Neurology"},{"issue":"1","key":"168_CR29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcv.2011.10.003","volume":"53","author":"T Plavina","year":"2012","unstructured":"Plavina T, Berman M, Njenga M, et al. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol. 2012;53(1):65\u201371.","journal-title":"J Clin Virol"},{"issue":"5","key":"168_CR30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","volume":"70","author":"C Bozic","year":"2011","unstructured":"Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70(5):742\u201350.","journal-title":"Ann Neurol"},{"issue":"2","key":"168_CR31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","volume":"57","author":"P Lee","year":"2013","unstructured":"Lee P, Plavina T, Castro A, et al. A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol. 2013;57(2):141\u20136.","journal-title":"J Clin Virol"},{"issue":"3","key":"168_CR32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295\u2013303.","journal-title":"Ann Neurol"},{"issue":"1","key":"168_CR33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","volume":"74","author":"JR Berger","year":"2013","unstructured":"Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ. JC virus antibody status underestimates infection rates. Ann Neurol. 2013;74(1):84\u201390.","journal-title":"Ann Neurol"},{"issue":"23","key":"168_CR34","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMc1214233","volume":"368","author":"EO Major","year":"2013","unstructured":"Major EO, Frohman E, Douek D. JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med. 2013;368(23):2240\u20131.","journal-title":"N Engl J Med"},{"issue":"3","key":"168_CR35","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11481-012-9366-z","volume":"7","author":"A Laroni","year":"2012","unstructured":"Laroni A, Giacomazzi CG, Grimaldi L, et al. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J Neuroimmune Pharmacol. 2012;7(3):665\u201372.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"3","key":"168_CR36","doi-asserted-by":"crossref","first-page":"e1000363","DOI":"10.1371\/journal.ppat.1000363","volume":"5","author":"JM Kean","year":"2009","unstructured":"Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5(3):e1000363.","journal-title":"PLoS Pathog"},{"issue":"1\u20132","key":"168_CR37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.05.009","volume":"261","author":"J Lin","year":"2013","unstructured":"Lin J, Bettin P, Lee JK, Ho JK, Sadiq SA. Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab. J Neuroimmunol. 2013;261(1\u20132):123\u20138.","journal-title":"J Neuroimmunol"},{"key":"168_CR38","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Ticho B. Use of JC virus antibody index to stratify risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosis [oral communication]. ENS Congress, Barcelona, June 2013."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-014-0168-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0168-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:41:11Z","timestamp":1746272471000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-014-0168-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,19]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["168"],"URL":"https:\/\/doi.org\/10.1007\/s40263-014-0168-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,19]]}}}